KALA BIO, Inc. (NASDAQ:KALA) CEO Sells $72,048.00 in Stock

KALA BIO, Inc. (NASDAQ:KALA) CEO Mark T. Iwicki sold 15,168 shares of the business’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $4.75, for a total transaction of $72,048.00. Following the sale, the chief executive officer now owns 263,755 shares of the company’s stock, valued at $1,252,836.25. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

KALA BIO Trading Up 9.9 %

Shares of KALA stock opened at $7.09 on Friday. KALA BIO, Inc. has a 1 year low of $4.21 and a 1 year high of $16.11. The firm has a fifty day moving average price of $6.39 and a 200-day moving average price of $7.02. The company has a debt-to-equity ratio of 4.92, a current ratio of 4.22 and a quick ratio of 4.22. The company has a market cap of $19.99 million, a price-to-earnings ratio of -0.47 and a beta of -1.97.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($4.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.89) by ($1.31). As a group, equities analysts predict that KALA BIO, Inc. will post -14.49 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in KALA BIO stock. Tower Research Capital LLC TRC bought a new position in KALA BIO, Inc. (NASDAQ:KALA) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 4,357 shares of the company’s stock, valued at approximately $30,000. Tower Research Capital LLC TRC owned 0.16% of KALA BIO as of its most recent filing with the SEC. Institutional investors and hedge funds own 24.61% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on KALA shares. HC Wainwright decreased their target price on shares of KALA BIO from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, May 17th. Oppenheimer reissued an “outperform” rating and set a $15.00 price objective on shares of KALA BIO in a research report on Monday, April 1st.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.